Smoking Cessation May Reduce Risk of Visual Field Progression in Heavy Smokers
- PMID: 35939832
- PMCID: PMC10814878
- DOI: 10.1097/IJG.0000000000002092
Smoking Cessation May Reduce Risk of Visual Field Progression in Heavy Smokers
Abstract
Prcis: The earlier a person quits smoking the more likely is the optic nerve be spared from damage.
Purpose: To investigate the effect of smoking cessation on visual field (VF) progression in glaucoma.
Methods: Primary open angle glaucoma patients with a minimum of 3 years follow-up and 5 VFs were included. Linear mixed models were used to investigate the effects of smoking on the rates of 24-2 VF mean deviation loss after adjusting for confounding factors. Cox proportional hazard regression was used to identify whether different levels of smoking intensity were associated with VF progression with respect to different duration of quitting.
Results: Five hundred eleven eyes of 354 patients were included over the mean follow-up of 12.4 years. Mean baseline age (95% confidence interval) was 62.3 (61.2, 63.4) years. One hundred forty nine (42.1%) patients were smokers. In a multivariable model, smoking intensity was associated with faster VF loss (-0.06, 95% confidence interval (-0.10, -0.01) dB/year per 10 pack-years, P =0.01) among smokers. Heavy smokers (≥20 pack-years) who had quit ˂25 years prior had significantly greater odds of VF progression compared with never smokers (odds ratio=2.49 (1.01, 6.08); P =0.046). There was no significant difference in odds of VF progression in heavy smokers who had quit smoking more than 25 years compared with never smokers ( P =0.43). A significantly higher proportion of VF progression was found in heavy smokers who quit < 25 years compared with heavy smokers who quit ≥25 years by Kaplan-Meier analysis ( P =<0.001).
Conclusions: After ≥25 years of smoking cessation, the risk of VF progression in former heavy smokers becomes similar to never smokers. Long-term smoking cessation may be associated with lower VF progression in glaucoma patients.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Disclosure: R.N.W. has received financial support from C: Aerie Pharmaceuticals, Allergan, Equinox, Eyenovia, Nicox, Topcon; F: Heidelberg Engineering, Carl Zeiss Meditec, Konan Medical, Optovue, Centervue, Bausch&Lomb, Topcon; P: Toromedes, Carl Zeiss Meditec, Topcon. C.A.G. has received financial support from National Eye Institute, EyeSight Foundation of Alabama, Research to Prevent Blindness, Heidelberg Engineering, GmbH. J.M.L. has received financial support from C: Alcon, Allergan, Bausch & Lomb, Carl Zeiss Meditec, Heidelberg Engineering, Reichert, Valeant Pharmaceuticals; F: Bausch & Lomb, Carl Zeiss Meditec, Heidelberg Engineering, National Eye Institute, Novartis, Optovue, Reichert Technologies, Research to Prevent Blindness. The remaining authors declare no conflict of interest.
Figures


Similar articles
-
Impact of Smoking on Visual Field Progression in a Long-term Clinical Follow-up.Ophthalmology. 2022 Nov;129(11):1235-1244. doi: 10.1016/j.ophtha.2022.06.017. Epub 2022 Jun 23. Ophthalmology. 2022. PMID: 35752211 Free PMC article.
-
Pointwise Methods to Measure Long-term Visual Field Progression in Glaucoma.JAMA Ophthalmol. 2020 May 1;138(5):536-543. doi: 10.1001/jamaophthalmol.2020.0647. JAMA Ophthalmol. 2020. PMID: 32239185 Free PMC article.
-
Risk of Visual Field Progression in Glaucoma Patients with Progressive Retinal Nerve Fiber Layer Thinning: A 5-Year Prospective Study.Ophthalmology. 2016 Jun;123(6):1201-10. doi: 10.1016/j.ophtha.2016.02.017. Epub 2016 Mar 19. Ophthalmology. 2016. PMID: 27001534
-
Association Between Progressive Retinal Capillary Density Loss and Visual Field Progression in Open-Angle Glaucoma Patients According to Disease Stage.Am J Ophthalmol. 2021 Jun;226:137-147. doi: 10.1016/j.ajo.2021.01.015. Epub 2021 Jan 30. Am J Ophthalmol. 2021. PMID: 33524366
-
Multilayer Macula Vessel Density and Visual Field Progression in Glaucoma.Am J Ophthalmol. 2022 May;237:193-203. doi: 10.1016/j.ajo.2021.11.018. Epub 2021 Nov 19. Am J Ophthalmol. 2022. PMID: 34801510 Free PMC article.
Cited by
-
Disparities in Eye Care Utilization Among Refugee and Migrant Populations.Transl Vis Sci Technol. 2024 Feb 1;13(2):14. doi: 10.1167/tvst.13.2.14. Transl Vis Sci Technol. 2024. PMID: 38376863 Free PMC article.
-
Intraocular pressure increases the rate of macular vessel density loss in glaucoma.Br J Ophthalmol. 2024 Jan 29;108(2):181-187. doi: 10.1136/bjo-2022-322261. Br J Ophthalmol. 2024. PMID: 36535749 Free PMC article.
-
Associations of smoking and alcohol consumption with the development of open angle glaucoma: a retrospective cohort study.BMJ Open. 2023 Oct 4;13(10):e072163. doi: 10.1136/bmjopen-2023-072163. BMJ Open. 2023. PMID: 37793935 Free PMC article.
-
The role of matrix metalloproteinases in the modulation of aqueous humor in glaucoma patients.Rom J Ophthalmol. 2025 Apr-Jun;69(2):208-211. doi: 10.22336/rjo.2025.33. Rom J Ophthalmol. 2025. PMID: 40698094 Free PMC article. Review.
-
Association of smoking cessation patterns and untreated smoking with glaucoma, cataract, and macular degeneration: a population-based retrospective study.Sci Rep. 2024 Jun 26;14(1):14788. doi: 10.1038/s41598-024-65813-8. Sci Rep. 2024. PMID: 38926484 Free PMC article.
References
-
- Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008;53 Suppl1:S3–10. - PubMed
-
- Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(11):1965–1972. - PubMed
-
- Perez CI, Singh K, Lin S. Relationship of lifestyle, exercise, and nutrition with glaucoma. Curr Opin Ophthalmol. 2019;30(2):82–88. - PubMed